Summary
EudraCT Number: 2009-015162-57
Sponsor's Protocol Code Number: P06153
National Competent Authority: Spain - AEMPS 
Clinical Trial Type: EEA CTA
Trial Status: Prematurely Ended
Date on which this record was first entered in the EudraCT database: 2011-03-31
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015162-57/ES/

A. Protocol Information
A.1 Member State Concerned: Spain - AEMPS
A.2 EudraCT number: 2009-015162-57
A.3 Full title of the trial: Estudio de extensión de fase 3, de 40 semanas, controlado con tratamiento activo, doble ciego y doble simulación del preladenant en sujetos con enfermedad de Parkinson de moderada a grave (fase 3; n. de protocolo P06153)
A.4.1 Sponsor's protocol code number: P06153
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: Schering-Plough Research Institute, a division of Schering Corporation
B.1.3.4	Country: United States
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: No
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Preladenant
D.3.2 Product code: SCH 420814
D.3.4 Pharmaceutical form: Coated tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Preladenant
D.3.9.1 CAS number: 377727-87-2
D.3.9.2 Current sponsor code: SCH 420814
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: range
D.3.10.3 Concentration number: 2 to 10
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 2
D.1.2 and D.1.3 IMP Role: Comparator
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Azilect
D.2.1.1.2 Name of the Marketing Authorisation holder: Lundbeck (Schweiz) AG
D.2.1.2 Country which granted the Marketing Authorisation: Switzerland
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Azilect
D.3.4 Pharmaceutical form: Capsule, hard
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Rasagiline mesylate
D.3.9.1 CAS number: 161735-79-1
D.3.9.3 Other descriptive name: RASAGILINE MESILATE
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 1 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 3
D.1.2 and D.1.3 IMP Role: Comparator
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Azilect
D.2.1.1.2 Name of the Marketing Authorisation holder: Teva Pharma GmbH
D.2.1.2 Country which granted the Marketing Authorisation: Germany
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Azilect
D.3.4 Pharmaceutical form: Capsule, hard
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Rasagiline mesylate
D.3.9.1 CAS number: 161735-79-1
D.3.9.3 Other descriptive name: RASAGILINE MESILATE
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 1 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo
D.8 Placebo: 1
D.8.1 Is a Placebo used in this Trial? Yes
D.8.3 Pharmaceutical form of the placebo: Coated tablet
D.8.4 Route of administration of the placebo: Oral use
D.8 Placebo: 2
D.8.1 Is a Placebo used in this Trial? Yes
D.8.3 Pharmaceutical form of the placebo: Capsule
D.8.4 Route of administration of the placebo: Oral use

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Enfermedad de Parkinson
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 13.1
E.1.2 Level: PT
E.1.2 Classification code: 10061536
E.1.2 Term: Parkinson's disease
E.1.2 System Organ Class: 10029205 - Nervous system disorders
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: Evaluar la seguridad y tolerabilidad a largo plazo del preladenant en sujetos con enfermedad de Parkinson (EP) de moderada a grave.
E.2.2 Secondary objectives of the trial: Caracterizar la eficacia a largo plazo del preladenant en sujetos con EP de moderada a grave.
E.2.3 Trial contains a sub-study: No
E.3 Principal inclusion criteria: En este ensayo participarán sujetos adultos con un diagnóstico al inicio del ensayo original (P04938 o P07037) de enfermedad de Parkinson de moderada a grave con presencia de fluctuaciones motoras que hayan completado el periodo de tratamiento de 12 semanas del ensayo original.Los sujetos deben haber completado el ensayo P04938 o P07037.
Cada sujeto (o su representante legal) debe estar dispuesto a dar su consentimiento informado por escrito para el ensayo P06153 y ser capaz de hacerlo. En el caso de que un sujeto no pueda dar su consentimiento independiente, un representante legal puede dar su consentimiento informado por escrito.
Los sujetos deben poder cumplir los calendarios de dosis y visitas.
Los sujetos deben estar bajo tratamiento con levodopa (L-dopa).
Los sujetos pueden estar recibiendo tratamiento con cualquier otra medicación complementaria adicional para la EP incluida en la siguiente tabla.
Nota: Los sujetos que únicamente reciben tratamiento con L-dopa pueden incluirse en este ensayo.
(Amantadina, Anticolinérgicos, Inhibidores de la dopa descarboxilasa, Agonistas de la dopamina, Entacapona, L-dopa)
Cada sujeto debe presentar resultados de análisis clínicos de laboratorio (hematología, bioquímica y análisis de orina) dentro de los límites normales o clínicamente aceptables para el investigador según se demuestre en los últimos resultados de análisis disponibles del estudio original (P04938 o P07037), y ningún resultado se situará dentro de los parámetros de exclusión descritos a continuación en los criterios de exclusión relativos a hallazgos hepáticos.
No ha habido cambios en el estado serológico o no se han producido hallazgos que justifiquen su determinación (para citomegalovirus [CMV], virus de Epstein-Barr [VEB] y hepatitis B, C y E).
Cada sujeto debe presentar resultados de una exploración física dentro de los límites normales, incluyendo una presión arterial dentro de los límites normales o límites clínicamente aceptables para el investigador y fuera de los parámetros de exclusión descritos a continuación en los criterios de exclusión para la presión arterial.
Todos los sujetos sexualmente activos o que tengan previsto ser sexualmente activos deben acceder a utilizar un método anticonceptivo altamente eficaz durante la participación del sujeto en el estudio y durante las dos semanas posteriores a la última dosis del fármaco del estudio. Los sujetos de sexo masculino no deben donar esperma en las dos semanas posteriores a la última dosis del fármaco del estudio. Los datos completos sobre los requisitos anticonceptivos se especifican en la sección 7.7.1.7 del protocolo.
E.4 Principal exclusion criteria: El sujeto no debe haber sido retirado de los ensayos P04938 o P07037 bajo ningún concepto.
El sujeto no debe presentar una enfermedad médica inestable grave o en curso (p. ej., cualquier enfermedad cardíaca clínicamente significativa, hipotensión ortostática sintomática, epilepsia o dependencia de alcohol/drogas).
El sujeto no debe presentar diabetes mal controlada (por ejemplo, HbA1c > 8,5) o una función renal significativamente anormal (p. ej., creatinina > 2,0 mg/dl) en opinión del investigador.
Como continuación de los criterios de retirada de tipo hepático de los estudios originales (P04938 y P07037), cualquier sujeto con valores elevados de alanina aminotransferasa (ALT) aspartato aminotransferasa (AST) o bilirrubina total (BIL-T), según se demuestre en los resultados del análisis más reciente de bioquímica en el estudio original, que cumpla uno de los siguientes criterios:
ALT o AST > 8 x LSN.
ALT o AST > 5 x LSN durante más de dos semanas.
ALT o AST > 3 x LSN y (BIL-T > 2 x LSN o índice normalizado internacional [INR] > 1,5 por causa distinta a anticoagulación) en la misma visita.
ALT o AST > 3 x LSN con aparición de agravación de la fatiga, náuseas, vómitos, dolor o dolor a la palpación en el cuadrante superior derecho, fiebre, erupción cutánea y/o eosinofilia (> 5%).
Como continuación de los criterios de retirada de la presión arterial (PA) de los estudios originales (P04938 y P07037), cualquier sujeto que cumpla los siguientes criterios en la segunda de dos visitas consecutivas separadas por siete días (es decir, el sujeto ya cumple uno de los criterios de PA siete días antes de la visita de selección del estudio P06153):
PA sistólica > o = 180 mm Hg o PA diastólica > o = 105 mm Hg, o
Una elevación de la PA inicial en el estudio original (P04938 o P07037) de la PA sistólica >  o = 40 mm Hg o de la PA diastólica > o =20 mm Hg.
El sujeto no debe presentar antecedentes de cáncer primario o recurrente en los cinco últimos años, con la excepción del cáncer de piel de células basales o células escamosas adecuadamente tratado, cáncer cervical in situ o cáncer de próstata in situ con antígeno prostático específico (PSA) normal después de la resección.
El sujeto no debe presentar un consumo diario medio de más de 180 ml de vino o equivalente.
Medicamentos concomitantes prohibidos: El sujeto no debe recibir tratamiento o iniciar tratamiento con ninguno de los medicamentos enumerados en la siguiente tabla.
El sujeto no debe haber recibido tratamiento con ninguno de los medicamentos incluidos en la siguiente tabla en un periodo menor que el indicado antes del día 1 del estudio P06153.
Nota: Deben seguirse las advertencias y contraindicaciones indicadas en la información de prescripción para los medicamentos permitidos (mostrados en los criterios de inclusión).
E.5 End points
E.5.1 Primary end point(s): Los criterios de valoración de la seguridad están relacionados con el objetivo principal del ensayo. Los criterios de valoración de la eficacia incluirán los cambios desde el inicio en cada uno de los siguientes elementos:
Puntuación de la MoCA; Puntuación del EQ-5D; Puntuación del PDQ-39; Puntuación del BDI-II; Puntuación de la Escala de la Apatía; Datos del diario que incluyen los siguientes criterios de valoración de la eficacia: Media de horas al día en estado off, Media de horas al día en estado on, Media de horas al día en estado on sin discinesias molestas, Media de horas al día en estado on con discinesias molestas, Proporción de tiempo on sin discinesias, Proporción de tiempo on sin discinesias molestas, Proporción de tiempo on con discinesias molestas, Tiempo total medio de sueño; Puntuación total del UPDRS en estado on: Puntuación del UPDRS para las partes 1, 2 y 3 combinadas, Puntuación del UPDRS para las partes 2 y 3 combinadas, Puntuaciones de las subescalas del UPDRS para las partes 1, 2, 3 y 4, Dominio del temblor del UPDRS, parte 3.
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: No
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: Information not present in EudraCT
E.7.1.2 Bioequivalence study: Information not present in EudraCT
E.7.1.3 Other: Information not present in EudraCT
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): No
E.7.3 Therapeutic confirmatory (Phase III): Yes
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: No
E.8.1.3 Single blind: No
E.8.1.4 Double blind: Yes
E.8.1.5 Parallel group: Yes
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): Yes
E.8.2.2 Placebo: No
E.8.2.3 Other: No
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.4.1 Number of sites anticipated in Member State concerned: 5
E.8.5 The trial involves multiple Member States: Yes
E.8.5.1 Number of sites anticipated in the EEA: 73
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: Yes
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned:
E.8.7 Trial has a data monitoring committee: Yes
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: Last Subject Last Visit
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 2
E.8.9.1 In the Member State concerned months: 6
E.8.9.1 In the Member State concerned days: 0
E.8.9.2 In all countries concerned by the trial years: 2
E.8.9.2 In all countries concerned by the trial months: 6
E.8.9.2 In all countries concerned by the trial days: 0

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Information not present in EudraCT
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Yes
F.3.3.1 Women of childbearing potential not using contraception : No
F.3.3.2 Women of child-bearing potential using contraception: Yes
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 35
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 480
F.4.2.2 In the whole clinical trial: 750

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2011-05-23
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2011-05-12

P. End of Trial
P. End of Trial Status: Prematurely Ended
P. Date of the global end of the trial: 2013-05-23

